There’s A Therapeutic Curveball Heading For The FDA
Los Angeles, California-based Puma Biotechnology has shuffled a challenging new drug application (NDA) onto FDA’s desk.
Neratinib has polarized experts and investors over the last few weeks, with its data flaws and dubious benefit-to-risk ratio. The drug is currently under review for use in breast cancer patients who have had their tumors surgically removed.
Neratinib has polarized experts and investors over the last few weeks, with its data flaws and dubious benefit-to-risk ratio. The drug is currently under review for use in breast cancer patients who have had their tumors surgically removed.